J
Judith de Vos-Geelen
Researcher at Maastricht University Medical Centre
Publications - 83
Citations - 1820
Judith de Vos-Geelen is an academic researcher from Maastricht University Medical Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 14, co-authored 48 publications receiving 834 citations. Previous affiliations of Judith de Vos-Geelen include Maastricht University.
Papers
More filters
Journal ArticleDOI
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Eva Versteijne,Mustafa Suker,K.B.C. Groothuis,Janine M Akkermans-Vogelaar,Marc G. Besselink,Bert A. Bonsing,Jeroen Buijsen,Olivier R. Busch,Geert-Jan Creemers,Ronald M. van Dam,Ferry A.L.M. Eskens,Sebastiaan Festen,Jan Willem B. de Groot,Bas Groot Koerkamp,Ignace H. J. T. de Hingh,Marjolein Y.V. Homs,Jeanin E. van Hooft,Emile D Kerver,Saskia A C Luelmo,Karen J. Neelis,Joost J. Nuyttens,G. Paardekooper,Gijs A. Patijn,Maurice J.C. van der Sangen,Judith de Vos-Geelen,Johanna W. Wilmink,Aeilko H. Zwinderman,Cornelis J. A. Punt,Casper H.J. van Eijck,Geertjan van Tienhoven +29 more
TL;DR: Although the outcomes of the secondary end points and predefined subgroup analyses suggest an advantage of the neoadjuvant approach, additional evidence is required.
Journal ArticleDOI
Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial
Eva Versteijne,Casper H.J. van Eijck,Cornelis J. A. Punt,Mustafa Suker,Aeilko H. Zwinderman,Miriam A. C. Dohmen,K.B.C. Groothuis,O. R. C. Busch,Marc G. Besselink,Ignace H. J. T. de Hingh,Albert J. ten Tije,Gijs A. Patijn,Bert A. Bonsing,Judith de Vos-Geelen,Joost M. Klaase,Sebastiaan Festen,Djamila Boerma,Joris I. Erdmann,I. Quintus Molenaar,Erwin van der Harst,Marion van der Kolk,Coen R.N. Rasch,Geertjan van Tienhoven +22 more
TL;DR: The PREOPANC phase III trial aims to test the hypothesis that median overall survival of patients with resectable or borderline resectables pancreatic cancer can be improved with preoperative radiochemotherapy, and investigates whether preoperative Radiochemotherapy improves overall survival by means of increased resection rates.
Journal ArticleDOI
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
Eva Versteijne,Jacob L van Dam,Mustafa Suker,Quisette P. Janssen,Karin B. C. Groothuis,Janine M Akkermans-Vogelaar,Marc G. Besselink,Bert A. Bonsing,Jeroen Buijsen,Olivier R. Busch,Geert-Jan Creemers,Ronald M. van Dam,Ferry A.L.M. Eskens,Sebastiaan Festen,Jan Willem B. de Groot,Bas Groot Koerkamp,Ignace H. J. T. de Hingh,Marjolein Y.V. Homs,Jeanin E. van Hooft,Emile D Kerver,Saskia A C Luelmo,Karen J. Neelis,Joost J. Nuyttens,G. Paardekooper,Gijs A. Patijn,Maurice J.C. van der Sangen,Judith de Vos-Geelen,Johanna W. Wilmink,Aeilko H. Zwinderman,Cornelis J. A. Punt,Geertjan van Tienhoven,Casper H.J. van Eijck +31 more
TL;DR: Neoadjuvant gem citabine-based chemoradiotherapy followed by surgery and adjuvant gemcitabine improves OS compared with upfront surgery and adenovation in resectables and borderline resectable pancreatic cancer.
Journal ArticleDOI
Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma
Anouk E J Latenstein,Lydia G. M. van der Geest,Bert A. Bonsing,Bas Groot Koerkamp,Nadia Haj Mohammad,Ignace H. J. T. de Hingh,Vincent E de Meijer,I. Q. Molenaar,Hjalmar C. van Santvoort,Geertjan van Tienhoven,Joanne Verheij,Pauline A. J. Vissers,Judith de Vos-Geelen,Olivier R. Busch,Casper H.J. van Eijck,Hanneke W. M. van Laarhoven,Marc G. Besselink,Johanna W. Wilmink +17 more
TL;DR: The incidence of pancreatic ductal adenocarcinoma increased in the past two decades and use of adjuvant or palliative chemotherapy increased with improved survival in these patients.
Journal ArticleDOI
Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study.
Marin Strijker,Ali Belkouz,Lydia G. M. van der Geest,Thomas M. van Gulik,Jeanin E. van Hooft,Vincent E de Meijer,Nadia Haj Mohammad,Philip R. de Reuver,Joanne Verheij,Judith de Vos-Geelen,Johanna W. Wilmink,Bas Groot Koerkamp,Heinz-Josef Klümpen,Marc G. Besselink +13 more
TL;DR: In a nationwide cohort of DCC, resection rates and the use of chemotherapy increased whereas OS remained stable at 10.4 months, and independent poor prognostic factors for OS in resected disease were increasing age, pT3/T4 stage, higher lymph node ratio, poor differentiation, and R1 resection.